KATRD
LOGIN
- KATRD 2021 International Conference
-
November 7(Thu)-8(Fri), 2020 Lotte Hotel World, Seoul, Kore
Program in Detail
한국어 진행 강의입니다.
|
Plenary Session 1 |
13:30-14:10 |
||
|---|---|---|---|
| Chair | |||
| 08:30-09:00 | PS 1-1 |
Approach and Management of Elderly Lung Cancer Patients in Super-aged Society
|
|
| 09:00-09:30 | PS 1-2 |
The Importance of Effective Registries in Pulmonary Diseases and How to Optimize Their Output
|
|
| 09:30-10:00 | PS 1-3 |
Update of Combined Pulmonary Fibrosis and Emphysema (CPFE)
|
|
|
Break |
14:10-14:50 |
||
|
[Symposium 01] Airway Disease 1 - Controversies and Perspectives in Airway Diseases |
15:10-16:30 |
||
| Chair | |||
| 10:30-11:00 | SY 1-1 |
Controversies and Opportunities in Severe Asthma
|
|
| 11:00-11:30 | SY 1-2 |
Current Controversies and Future Perspectives in COPD
|
|
| 11:30-12:00 | SY 1-3 |
The Importance of Real-life Research in Respiratory Medicine
|
|
|
[Symposium 04] Interstitial Lung Disease 1 - Wide Spectrum of Fibrotic Lung Diseases in Real World |
15:10-16:30 |
||
| Chair | |||
| 10:30-11:00 | SY 4-1 |
Wide Spectrum of Fibrotic Lung Disease in Real World
|
|
| 11:00-11:30 | SY 4-2 |
Diagnosis and Management of Interstitial Lung Disease in Rheumatoid Arthritis
|
|
| 11:30-12:00 | SY 4-3 |
SSc-ILD: Current Evidences and Application
|
|
|
[Symposium 07] Lung Cancer 1 - New Applicable Biomarkers in Lung Cancer |
15:10-16:30 |
||
| Chair | |||
| 10:30-11:00 | SY 7-1 |
Navigating the Evolving NSCLC 1L Treatment Landscape with a Focus on Nivolumab + Ipilimumab
|
|
| 11:00-11:30 | SY 7-2 |
Current Achievement and Future Perspective of Genome Profiling by Liquid Biopsy
|
|
| 11:30-12:00 | SY 7-3 |
Imaging Biomarkers in Lung Cancer
|
|
|
[Symposium 19] Management of Airway Diseases in Asia |
15:10-16:30 |
||
| Chair | |||
| 10:30-11:00 | SY 19-1 |
Early Detection and Management of COPD
|
|
| 11:00-11:30 | SY 19-2 |
Philippine COPD Pathway Project
|
|
| 11:30-12:00 | SY 19-3 |
Diagnosis and Management of Benign Central Airway Stenosis: Experience from Vietnam
|
|
|
[Luncheon Symposium 01] Airway Disease 
|
11:00-12:00 |
||
| Chair | |||
| 12:00-12:30 | LS 1 |
Which Types of Asthma Patients Would Benefit from Omalizumab?
|
|
|
[Luncheon Symposium 02] Interstitial Lung Disease 
|
11:00-12:00 |
||
| Chair | |||
| 12:00-12:30 | LS 2 |
Antifibrotic Therapy in Japan: Long Term Treatment Experience of Pirfenidone
|
|
|
[Luncheon Symposium 03] Lung Cancer 
|
11:00-12:00 |
||
| Chair | |||
| 12:00-12:30 | LS 3 |
Transform Treatment Strategy for EGFRm NSCLC Patients from Early to Advanced Stage
|
|
|
Break |
12:20-13:30 |
||
|
[Symposium 02] Airway Disease 2 - Current and Future of Using Biomarkers in the Management of Airway Diseases |
15:10-16:00 |
||
| Chair | |||
| 13:30-14:00 | SY 2-1 |
Blood and Sputum Eosinophil as a Biomarker of COPD
|
|
| 14:00-14:30 | SY 2-2 |
Biomarkers and Biologics for Severe Asthma
|
|
| 14:30-15:00 | SY 2-3 |
Multi-Omics Based Precision Medicine in Asthma
|
|
|
[Symposium 05] Interstitial Lung Disease 2 - Update of Rare and Orphan Lung Diseases |
15:10-16:00 |
||
| Chair | |||
| 13:30-14:00 | SY 5-1 |
Pulmonary Alveolar Proteinosis: No Longer Orphan in New Era?
|
|
| 14:00-14:30 | SY 5-2 |
Lymphangioleiomatosis
|
|
| 14:30-15:00 | SY 5-3 |
Pleuroparenchymal Fibroelastosis (PPFE)
|
|
|
[Symposium 08] Lung Cancer 2 - Additional Treatment: Worthwhile and When |
15:10-16:00 |
||
| Chair | |||
| 13:30-14:00 | SY 8-1 |
Adjuvant Chemotherapy of Completely Resected Stage 1 Non-Small Cell Lung Cancer
|
|
| 14:00-14:30 | SY 8-2 |
Abscopal Effect of Radiotherapy Combined with Immune Checkpoint Inhibitors
|
|
| 14:30-15:00 | SY 8-3 |
Salvage Surgery for Non-Small Cell Lung Cancer After Tyrosine Kinase Inhibitor Treatment
|
|
|
Break |
15:50-16:30 |
||
|
[Symposium 03] Environmental Lung Disease - Hot Topics in Environmental Lung Diseases in 2021 |
08:00-08:50 |
||
| Chair | |||
| 15:30-16:00 | SY 3-1 |
Humidifier Disinfectant (HD) and Bronchial Asthma
|
|
| 16:00-16:30 | SY 3-2 |
Climate Change and Related Medical Problems
|
|
| 16:30-17:00 | SY 3-3 |
Changes in Air Pollution during the COVID-19 Pandemic and Related Health Effects
|
|
|
[Symposium 06] Tuberculosis - Beyond the Current Treatment of Tuberculosis |
08:00-08:50 |
||
| Chair | |||
| 15:30-16:00 | SY 6-1 |
Personalized Therapy for TB
|
|
| 16:00-16:30 | SY 6-2 |
Host-Directed Therapy for Tuberculosis
|
|
| 16:30-17:00 | SY 6-3 |
TB Co-infection among COVID Confirmed Patients – The Philippine Experience
|
|
|
[Symposium 09] Lung Cancer 3 - Beyond Standard Treatment |
08:00-08:50 |
||
| Chair | |||
| 15:30-16:00 | SY 9-1 |
The Emerging Therapeutic Landscape of ALK TKIs in Advanced NSCLC
|
|
| 16:00-16:30 | SY 9-2 |
Immune Checkpoint Inhibitors in NSCLC with Driver Mutations
|
|
| 16:30-17:00 | SY 9-3 |
Management of Brain Metastasis Considering Molecular Profiling
|
|
|
Break |
09:00-10:20 |
||
|
[Satellite Symposium 1] Airway Disease 
|
09:00-10:30 |
||
| Chair | |||
| 17:15-17:45 | SS 1-1 |
Why Wouldn’t We Intervene Earlier in Patients at Risk of Exacerbation?
|
|
| 17:45-18:15 | SS 1-2 |
Should You Initiate Treatment with One or Two Bronchodilators?
|
|
|
[Satellite Symposium 3] Interstitial Lung Disease / Airway Disease 
|
09:00-10:30 |
||
| Chair | |||
| 17:15-17:45 | SS 3-1 |
Exploring Optimal Treatment Options for Progressive Fibrosing ILDs : How to Treat?
|
|
| 17:45-18:15 | SS 3-2 |
What Do COPD Real World Studies Tell Us about LAMA/LABA Initiation in Maintenance Therapy?
|
|